Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
HIV Medicine|October 13, 2020
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitorsG Schuettfort, L Boekenkamp, A Cabello, et al.
Cancer Research|December 9, 2024
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell TumorsThomas Welte, Veena K Vuttaradhi, Eleonora Y Khlebus, et al.
Gynecologic Oncology|August 31, 2025
Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor modelsAllison L Brodsky, Thomas Welte, Veena K Vuttaradhi, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerRongjie Fu, Yalong Wang, Ishita Rehman, et al.
The Journal of Clinical Endocrinology and Metabolism|June 13, 2021
A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid CarcinomaYing C Henderson, Abdallah S R Mohamed, Anastasios Maniakas, et al.
Cancer Research Communications|May 21, 2026
Drug screening of sarcoma cells: finding shared sensitivitiesHannah C Beird, Carl Ho, Roberto Cardenas-Zuniga, et al.
Molecular Cancer Therapeutics|January 16, 2026
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer CellsJerry H Houl, Rozita Bagheri-Yarmand, Muthusamy Kunnimalaiyaan, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2025
Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsJerry H Houl, Rozita Bagheri-Yarmand, Muthusamy Kunnimalaiyaan, et al.
HIV Medicine|May 12, 2016
PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxisG Fätkenheuer, H Jessen, A Stoehr, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
Pageof 27